Gregory N. Gan, M.D., Ph.D.
Assistant Professor, Radiation Oncology
Assistant Professor, Cancer Biology
After receiving his Medical Degree from the University of Pittsburgh, Dr. Gregory Gan continued his education and went on to earn his Ph.D. in DNA Repair and Mutagenesis in the Department of Pharmacology.
Dr. Gan is an Assistant Professor at the University of Kansas Medical Center and Director of Oligometastatic and SBRT Program and Director of Technology Development. As both a radiation oncologist and physician-scientist, Dr. Gan's basic science research interest focuses on the tumor microenvironment, epithelial-to-mesenchymal transition (EMT) and radiation biology.
Education and Training
- PhD, DNA Repair and Mutagenesis, University of Pittsburgh, SOM, Pittsburgh, PA
- MD, Doctor of Medicine, University of Pittsburgh, SOM, Pittsburgh, PA
- BS, Biology, Tufts University, Medford, MA
- Residency, Radiation Oncology, Anschutz Cancer Center, University of Colorado, Aurora, CO
Licensure, Accreditations & Certifications
- American Board of Radiology, American Board of Radiology
- Kansas License, Kansas Board of Healing Arts
- The University of Kansas Cancer Center, Radiation Oncology Executive Committee, Member, 2019 - Present
- NRG Oncology, Developmental Therapeutics Radiation Therapy (DTRT) Subcommittee, Member, 2018 - Present
- NRG Oncology, Head and Neck Cancer General Committee, Member, 2017 - Present
- American Association of Cancer Researchers, Member, 2012 - Present
- American Society of Therapeutic Radiation Oncology, Member, 2010 - Present
- American Medical Association , Member, 2000 - Present
Dr. Gan is pursuing translational research with the goal of developing novel treatment strategies for head and neck and thoracic cancers. Dr. Gan and his research team are testing the hypothesis that radiotherapy can up-regulate EMT which can lead to tumor repopulation, distant metastasis, and overall treatment resistance. He is ideally suited to address this question because of his fellowship training and expertise in establishing head and neck cancer patient-derived tumor xenografts mouse models, developing a model for mouse head and neck irradiation, and evaluating tumor stem cell biology and its respective microenvironment. Dr. Gan is also interested in how radiotherapy (particularly high dose per fraction also known as stereotactic body radiotherapy) and EMT may affect local and distant control rates in both HPV positive and negative head and neck cancers and thoracic malignancies. He became interested in this area because local control and overall survival remain very poor for patients with HPV negative head and neck cancers. Insights gained from a better understanding of why these tumors fail locally and distantly can potentially improve outcomes.
Current Research and Grants
- Idnetifying the Molecular Determinants Associated with Early Failure in Early-Stage Larynx Cancer Following defenitive Radiotherapy, KU Frontiers Program, PI
- Bergamo, A., M, Kauweloa, K, Gan, G, Zheng, S, Daniels, J, Crownover, R, Narayanasamy, G, Stathakis, S, Mavroidis, P, Papanikolaou, N, Gutierrez, A. 2019. Correlation between biological effective dose and radiation-induced liver disease from hypofractionated radiotherapy. J Med Phys, 44 (3), 185-190
- Smith, H, Morgan, D, Berggren, K., L, Hixon, M., D , Shen, X, Woolbright, B, Taylor, J, Gan, G., N. 2020. The MAPKAPK2 pathway mediates radiation-induced tumor inflammation and proliferation in bladder cancer
- Yilmaz, E, Cowan, A., T, Guo, Y, Lee, D., Y, Ozbun, M., A, Gan, G., N. 2020. FAT1 and CASP8 co-mutations are associated with poor prognosis in HPV negative head and neck squamous cell carcinoma